KALY Recommended A BUY At $0.01 With Potential To $0.10 After $5 Million CBD Extraction Contract Announcement

KALY Recommended A BUY At $0.01 With Potential To $0.10 After $5 Million CBD Extraction Contract Announcement

New York, NY -- June 5, 2019 -- InvestorsHub NewsWire -- via www.nextbigticker.com -- Kali-Extracts, Inc. (USOTC: KALY) is recommended a BUY today by AmericanBulls (americanbulls.com/KALY).  Yesterday, the company announced a CBD extraction contraction with a licensed hemp grower in the State of New York that is worth a potential $5 million dollars driving the company’s overall potential revenue in 2019 to $6 million.

Kali-Extracts Announces CBD Extraction Contract Estimated to Generate $5 Million in 2019 Revenue

AmericanBulls says …

“Let’s jump on our white horses and go for a bullish ride. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. The market is telling you about a new profit. Do not miss this bullish opportunity.”

Last Signal: BUY
Last Pattern: BULLISH DOJI STAR



KALY Potential PPS Run From $0.01 to $0.04 On Way To $0.10

The KALY PPS experienced a dramatic dip on Monday following Friday’s FDA non-committal comments on CBD and then rebounded on high volume on Tuesday.  Now KALY has a buy recommendation and is still below the almost $0.04 high it reached late last year after acquiring the US Patented Cannabis Extraction Process that is currently the center of the company’s growing value.  With KALY’s patented cannabis pharmaceutical research now coming to light, the PPS is positioned to shoot past the recent $0.04 highs to a level putting it on par with some of the other penny cannabis stock contenders.  A $0.10 PPS is not an unreasonable milestone after singing a $5 million CBD extraction contract.

KALY is providing CBD extracts for over $1 million worth of CBD infused water produced by Puration, Inc. (USOTC: PURA), and KALY has also introduced its own CBD infused gum, Hemp4mula available on North American Cannabis Holdings, Inc.’s website www.USMJ.com.  KALY is also implementing an extraction lab to process biomass from Nouveau’s (USOTC: NOUV) 100 acer hemp farm.

Following the acquisition of the patented cannabis extraction process late last year and the corresponding jump in price and trading volume, the OTC Markets flagged the company in response to the jump in activity.  The company has responded by updating all its OTC Markets required reports.  Management is likely to mitigate the OTC Market’s concerns sooner or later and see the flag removed which will likely be yet another impetus fueling a KALY PPS run. 

Management engaged Goldman Small Cap Research to conduct analyst coverage of the company and file an initial analyst report:  KALY Research Report

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com